Amova Asset Management Americas Inc. Grows Stock Holdings in Arcturus Therapeutics Holdings Inc. $ARCT

Amova Asset Management Americas Inc. grew its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 12.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,288,935 shares of the biotechnology company’s stock after purchasing an additional 262,347 shares during the quarter. Amova Asset Management Americas Inc. owned approximately 8.05% of Arcturus Therapeutics worth $17,648,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. ARK Investment Management LLC grew its holdings in Arcturus Therapeutics by 39.4% in the 4th quarter. ARK Investment Management LLC now owns 2,611,099 shares of the biotechnology company’s stock valued at $16,006,000 after buying an additional 738,378 shares during the period. Arrowstreet Capital Limited Partnership grew its holdings in Arcturus Therapeutics by 1,371.4% in the third quarter. Arrowstreet Capital Limited Partnership now owns 552,179 shares of the biotechnology company’s stock valued at $10,177,000 after purchasing an additional 514,652 shares during the period. Millennium Management LLC purchased a new position in Arcturus Therapeutics during the first quarter worth approximately $4,892,000. Bank of America Corp DE boosted its holdings in shares of Arcturus Therapeutics by 112.0% in the 3rd quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock valued at $11,428,000 after purchasing an additional 327,626 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Arcturus Therapeutics by 12.9% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,288,935 shares of the biotechnology company’s stock valued at $17,671,000 after purchasing an additional 262,347 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Down 1.3%

Shares of ARCT opened at $5.97 on Tuesday. The business has a fifty day moving average of $7.17 and a 200 day moving average of $7.48. The company has a market cap of $169.67 million, a PE ratio of -2.12 and a beta of 2.37. Arcturus Therapeutics Holdings Inc. has a 52-week low of $5.77 and a 52-week high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Friday, May 8th. The biotechnology company reported ($0.95) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.08. Arcturus Therapeutics had a negative net margin of 143.80% and a negative return on equity of 36.55%. The business had revenue of $2.06 million for the quarter, compared to the consensus estimate of $6.30 million. As a group, research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -3.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on ARCT shares. Wall Street Zen upgraded Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday. Weiss Ratings raised Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.25.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.